Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Invex Therapeutics Ltd. ( (AU:IXC) ) has issued an update.
Invex Therapeutics has launched an expanded preclinical research program with Tessara Therapeutics to investigate Exenatide and other GLP-1 receptor agonists in Tessara’s human iPSC-derived three-dimensional Alzheimer’s disease model, ADBrain™. The initiative follows earlier findings in the same model where Exenatide showed statistically significant improvements in multiple Alzheimer’s biomarkers and a potential neuroprotective effect against ferroptosis, an iron-dependent cell death pathway linked to neurodegeneration.
The new study will benchmark Exenatide against a current GLP-1 agonist, assess combination regimens with existing Alzheimer’s symptomatic treatments, and test novel combinations with naturally occurring factors that may enhance therapeutic effects. By focusing on cytotoxicity, cell viability, ferroptosis and mechanistic signatures, the program could broaden Invex’s neurological pipeline beyond intracranial pressure disorders and position the company in the competitive Alzheimer’s disease field if the results prove positive.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company focused on repurposing the already approved drug Exenatide to treat neurological conditions associated with raised intracranial pressure. The company has trademarked its repurposed Exenatide as Presendin™ and is targeting unmet needs in neurology by exploring novel mechanisms and indications beyond existing standard-of-care therapies.
Average Trading Volume: 26,125
Technical Sentiment Signal: Sell
Current Market Cap: A$7.52M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.